Chlorpheniramine and midazolam

PreclinicalSmall molecule

SSeoul National University Hospital

Chlorpheniramine and midazolam is one of 4 small molecule programs targeting Endoscopy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndoscopyUnknown status

EndoscopyPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Endoscopy

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Preclinical

2 2

Domperidone

Johnson & Johnson

Preclinical

1 3

Chlorpheniramine and midazolam

SSeoul National University Hospital

Preclinical

1 4

Indigo Carmine

HHillel Yaffe Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endoscopy1 trial

Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy

Unknown status·SSeoul National University Hospital·N/A·NCT03940391·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chlorpheniramine and midazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chlorpheniramine and midazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chlorpheniramine and midazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Chlorpheniramine and midazolam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endoscopy1 trial

References

Drug Info

Quick Facts

Related News